X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KN035 is an investigational PD-L1 antibody, which is currently being evaluated for the treatment of undifferentiated pleomorphic sarcoma & myxofibrosarcoma.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
KN035 (envafolimab) is a single-domain antibody against PD-L1. It isbeing evaluated in phase 2 clinical trials for the treatment of undifferentiated pleomorphic sarcoma & myxofibrosarcoma.
Lead Product(s): Envafolimab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
KN035 (envafolimab) is a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor, which is investigated for MSI-H/dMMR advanced solid tumors.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
KN035 (envafolimab) is a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor, which is investigated for MSI-H/dMMR advanced solid tumors.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alphamab Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
Envafolimab (KN035), a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
YH001 is an IgG1 antibody against CTLA-4 that has shown enhanced antibody dependent cellular cytotoxicity and complement dependent cytotoxicity in vitro. YH001 demonstrated superior T cell activation and superior tumor growth inhibition activity compared to ipilimumab.
Lead Product(s): YH001,Envafolimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: YH001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
Envafolimab (KN035), a single-domain antibody against PD-L1 is the first approved subcutaneously injected PD-(L)1 inhibitor. Envafolimab is currently being studied in the ENVASARC Phase 2 and a Phase 3 pivotal trial in advanced biliary tract cancer patients.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
Envafolimab (KN035), a single-domain antibody against PD-L1 invented by Alphamab Oncology, is the first approved subcutaneously injected PD-(L)1 inhibitor.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Runway Growth Capital LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 06, 2022
Details:
YH001 is an IgG1 antibody targeting CTLA-4,has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro when compared with ipilimumab.
Lead Product(s): YH001,Envafolimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: YH001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Biocytogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
Envafolimab (KN035), a single-domain antibody against PD-L1 invented by Alphamab Oncology, is the first approved subcutaneously injected PD-(L)1 inhibitor.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
